Publications de Patricia MARINO
The use of ‘added benefit’ to determine the price of new anti-cancer drugs in France, 2004–2017. European Journal of Cancer 2021 ; 145 : 11 - 18.
Impact of active surveillance for prostate cancer on the risk of depression and anxiety: Patient-reported outcomes (PROs) from the Vican Prospective Cohort. Journal of Clinical Oncology 2021 ; 39 (6SUPPL) : 220-220.
Impact of Next Generation Sequencing on Clinical Practice in Oncology in France: Better Genetic Profiles for Patients Improve Access to Experimental Treatments. Value in Health 2020 ; 23 (7) : pp. 898-906.
Quality of Life During Chemotherapy for Breast Cancer in a West African Population in Dakar, Senegal: A Prospective Study. Journal of Global Oncology 2019 ; 5 (5) : 1-9.
The role and use of Patient Reported Outcomes in the management of cancer patients. Bulletin du Cancer 2018 ; 105 (6) : 603-609.
Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study. European Journal of Human Genetics 2018 ; 26 (3) : pp. 314-323.
Sex Differences in the Return-to-Work Process of Cancer Survivors 2 Years After Diagnosis: Results From a Large French Population-Based Sample. Journal of Clinical Oncology 2013 ; 31 (10) : 1277-1284.
Economic issues involved in integrating genomic testing into clinical care: the case of genomic testing to guide decision-making about chemotherapy for breast cancer patients. Breast Cancer Research and Treatment 2010 ; 129 (2) : 401-409.
Cost-effectiveness of adjuvant docetaxel for node-positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology 2010 ; 21 (7) : 1448-1454.
Impact of uncertainty on cost-effectiveness analysis of medical strategies: The case of high-dose chemotherapy for breast cancer patients. International Journal of Technology Assessment in Health Care 2005 ; 21 : 342-350.